Pharmaceutical Executive-08-01-2004

Pediatric drugs require investments in formulation, but the market opportunity is worth the cost.

Backlash from a government VNR provides lessons for pharma PR.

We had a vision that this project deserved a company with a focus on HDL as the next frontier in the cardiovascular area.

Blockbusters may not grow on trees, but sometimes they hide in desk drawers. At least that's how it was for one of pharma's most enduring brands--one which, near the end of its patent life, boasts 16 indications, four formulations, and three (recent) billion-dollar years in a row.